Menin liver-specific hemizygous mice challenged with high fat diet show increased weight gain and markers of metabolic impairment

Nutrition and Diabetes

Volumn 2, Issue MAY, 2012, Pages

  Wuescher, L ^a   Angevine, K ^a   Patel, P R ^a   Mensah Osman, E ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Fatty liver; Menin; Metabolic syndrome; Type 2 diabetes

Indexed keywords

GLUCAGON; GLUCOKINASE; GLUCOSE; INSULIN; MENIN PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRIACYLGLYCEROL; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY LIVER; GENE DELETION; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN BLOOD LEVEL; LIPID DIET; LIPOGENESIS; METABOLIC REGULATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WEIGHT GAIN; WESTERN BLOTTING; WILD TYPE;

EID: 84880552090     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2012.7     Document Type: Article

References (43)

1. Balogh K, Pato'cs A, Hunyady L, Ra'cz K. Menin dynamics and functional insight: take your partners. Mol Cell Endocrinol 2010; 326: 80-84.
2. van Wijk JPH, Dreijerink KMA, Pieterman CRC, Lips CJM, Zelissen PMJ, Valk GD. Increased prevalence of impaired fasting glucose in MEN1 gene mutation carriers. Clin Endocrinol 2012; 76: 67-71.
3. McCallum RW, Parameswaran V, Burgess Jr. Multiple endocrine neoplasia type 1 (MEN 1) is associated with an increased prevalence of diabetes mellitus and impaired fasting glucose. Clin Endocrinol (Oxf) 2006; 65: 163-168.
4. Wuescher L, Angevine K, Hinds T, Ramakrishnan S, Najjar SM, Mensah-Osman EJ. Insulin regulates menin expression, cytoplasmic localization, and interaction with FOXO1. Am J Physiol Endocrinol Metab 2011; 301: E474-E483.
5. Liu Y, Dentin R, Chen D, Hedrick S, Ravnskjaer K, Schenk S et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 2008; 456: 269-273.
6. Estall JL, Kahn M, Cooper MP, Fisher FM, Wu MK, Laznik D et al. Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes 2009; 58: 1499-1508.
7. Agius L. New hepatic targets for glycaemic control in diabetes. Best Pract Res Clin Endocrinol Metab 2007; 21: 587-605.
8. Peter A, Stefan N, Cegan A, Walenta M, Wagner S, Königsrainer A et al. Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 2011; 96: E1126-E1130.
9. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
10. Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988; 12: 123-137.
11. Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K et al. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release 2005; 105: 89-105.
12. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846.
13. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
14. Tura A, Ludvik B, Nolan JJ, Pacini G, Thomaseth K. Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. Am J Physiol Endocrinol Metab 2001; 281: E966-E974.
15. Meier JJ, Holst JJ, Schmidt WE, Nauck MA. Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. Am J Physiol Endocrinol Metab 2007; 293: E849-E856.
16. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia. Diabetes Care 2008; 31(Supplement 2): S262-S268.
17. Dey A, Chandrasekaran K. Hyperglycemia induced changes in liver: in vivo and in vitro studies. Curr Diabetes Rev 2009; 5: 67-78.
18. Rossmeisl M, Rim JS, Koza RA, Kozak LP. Variation in type 2 diabetes - related traits in mouse strains susceptible to diet-induced obesity. Diabetes 2003; 52: 1958-1966.
19. Cheng P, Yang SS, Hu XG, Zhou XY, Zhang YJ, Jin G et al. Menin prevents liver steatosis through co-activation of peroxisome proliferator-activated receptor alpha. FEBS Lett 2011; 585: 3403-3408.
20. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007; 128: 837-847.
21. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43(2 Suppl 1): S99-S112.
22. Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab 2009; 296: E415-E421.
23. Hirota K, Sakamaki J, Ishida J, Shimamoto Y, Nishihara S, Kodama N et al. A combination of HNF-4 and Foxo1 is required for reciprocal transcriptional regulation of glucokinase and glucose-6-phosphatase genes in response to fasting and feeding. J Biol Chem 2008; 283: 32432-32441.
24. Ganjam GK, Dimova EY, Unterman TG, Kietzmann T. FoxO1 and HNF-4 are involved in regulation of hepatic glucokinase gene expression by resveratrol. J Biol Chem 2009; 284: 30783-30797.
25. Roth U, Jungermann K, Kietzmann T. Activation of glucokinase gene expression by hepatic nuclear factor 4alpha in primary hepatocytes. Biochem J 2002; 365: 223-228.
26. Schmidt SF, Mandrup S. Gene program-specific regulation of PGC-1a activity. Genes Dev 2011; 25: 1453-1458.
27. Ruiz-Rami'rez A, Cha'vez-Salgado M, Peñeda-Flores JA, Zapata E, Masso F, El-Hafidi M. High-sucrose diet increases ROS generation, FFA accumulation, UCP2 level, and proton leak in liver mitochondria. Am J Physiol Endocrinol Metab 2011; 301: E1198-E1207.
28. Jiang Y, Zhang H, Dong L-y, Wang D, An W. Increased hepatic UCP2 expression in rats with nonalcoholic steatohepatitis is associated with upregulation of Sp1 binding to its motif within the proximal promoter region. J Cell Biochem 2008; 105: 277-289.
29. Serviddio G, Bellanti F, Tamborra R, Rollo T, Capitanio N, Romano AD et al. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut 2008; 57: 957-965.
30. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999; 98: 115-124.
31. Rhee J, Ge H, Yang W, Fan M, Handschin C, Cooper M et al. Partnership of PGC-1a and HNF4a in the regulation of lipoprotein metabolism. J Biol Chem 2006; 281: 14683-14690.
32. Scacheri PC, Crabtree JS, Kennedy AL, Swain GP, Ward JM, Marx SJ et al. Homozygous loss of menin is well tolerated in liver, a tissue not affected in MEN1. Mamm Genome 2004; 15: 872-877.
33. Simeon IT. Deconstructing type 2 diabetes. Cell 1999; 97: 9-12.
34. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev 1998; 19: 608-624.
35. Winzell MS, Ahren B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 2004; 53(Suppl 3): S215-S219.
36. Heppner KM, Habegger KM, Day J, Pfluger PT, Perez-Tilve D, Ward B et al. Glucagon regulation of energy metabolism. Physiol Behav 2010; 100: 545-548.
37. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 2003; 284: E671-E678.
38. Gross DN, Wan M, Birnbaum MJ. The role of FOXO in the regulation of metabolism. Curr Diab Rep 2009; 9: 208-214.
39. Haeusler RA, Kaestner KH, Accili D. FoxOs function synergistically to promote glucose production. J Biol Chem 2010; 285: 35245-35248.
40. Leavens KF, Easton RM, Shulman GI, Previs SF, Birnbaum MJ. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab 2009; 10: 405-418.
41. Oiso H, Furukawa N, Suefuji M, Shimoda S, Ito A, Furumai R et al. The role of class I histone deacetylase (HDAC) on gluconeogenesis in liver. Biochem Biophys Res Commun 2011; 404: 166-172.
42. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001; 413: 131-138.
43. Oberkofler H, Klein K, Felder TK, Krempler F, Patsch W. Role of peroxisome proliferator-activated receptor-gamma coactivator-1alpha in the transcriptional regulation of the human uncoupling protein 2 gene in INS-1E cells. Endocrinology 2006; 147: 966-976.